Abstract:Objective To Explore the clinical features of early-onset severe preeclampsia and provide clinical evidence for early diagnosis,prognosis and termination of pregnancy.Methods 243 cases of severe preeclampsia fromJanuary 2009 to June 2011 in Gulouhospital were devided into two groups: the early onset group(n=74)and the late onset group(n=169).The general conditions,laboratory parameters,complications of pregnancy,outcomes of mothers and children were collected and the risk factors of adverse pregnancy outcomes of early-onset severe preeclampsia were analyzed by multifactor Logistic regression.Results No significant differences were found between the two groups in the average age,gravidities,parities and systematically antenatal checks(P>0.05),but significant differences were found in gestional ages at the onset of severe preeclampsia,delivery ages,and pregnant body mass index between the two groups.White blood cell count,red blood cell count,hematocrit,Alanine aminotransferase levels(ALT),Urea nitrogen levels(BUN),creatinine levels(Cr),and Diastolic blood pressure levels in the early onset group were significantly higher than those in the late onset group.The platelet count and Plasma total protein levels in the early onset group were significantly lower than those in the late onset group.No significant differences were found between the two groups in the Systolic blood pressure levels.The incidence of nervous system symptoms,digestive system symptoms,fundus hemorrhage,liver damages,hypoalbuminemia,palacental abruption,heart failure,and HELLP syndroms of mothers in the early onset group were significantly higher than those in the late onset group.The incidence of fetal growth retriction,fetal distress,premature delivery,newborns die and stillbirth in the early onset group were significantly higher than those in the late onset group.The higher red blood cell count,the lower platelet count and the higher alanine aminotransferase levels,the more likely abnormal outcomes of mothers and children in the early onsetgroup.Conclusion It is of great significance to master the clinical characteristics of ES-PE,positively predict the adverse pregnancy outcome risk factors,balance the interests of both mothers and children and timely terminate pregnancy in improving the prognosis of mothers and children.

Coagulation and Anti-Coagulation Treatment in Early Onset Severe Pre-Eclampsia

Study on Correlation between Changes in Coagulation and Fibrinolysis Related Factors and Incidence of Severe Pre-eclampsia

Emerging Pharmacologic Interventions for Pre-Eclampsia Treatment

Progress in Soluble Vascular Endothelial Growth Factor Receptor-1 and Preeclampsia

Effect of low-molecular-weight heparin calcium combined with magnesium sulfate and labetalol on coagulation, vascular endothelial function and pregnancy outcome in early-onset severe preeclampsia

Diagnosis and management of gestational hypertension and coagulation disorder

Changes of serum cardiotropin I and cystatin C in preeclampsia and significance thereof

Imbalance of Serum T Helper 1- and 2-Type Cytokines in Preeclampsia and Gestational Hypertension

A Clinical Trial on Early Onset Preeclampsia:the Curative Effect of Low Molecular Weight Heparin Calcium in Combining with Magnesium Sulfate

The Role of Anticoagulant Therapy in the Prevention of Preeclampsia Pharmacokinetic and pharmacodynamic mechanisms

Analysis of perinatal coagulation function in preeclampsia

Application of low molecular weight heparins in umbilical artery thrombosis: A case series and review of the literature.

Changes of serum cardiotropin Ⅰ and cystatin C in preeclampsia and clinical significance thereof

Association of Imbalanced Sex Hormone Production with Excessive Procoagulation Factor SerpinF2 in Preeclampsia

Changes of coagulation function and platelet parameters in preeclampsia and their correlation with pregnancy outcomes

Study on the Level Changes of N-terminal Pro-B-type Natriuretic Peptide in the Serum of Patients with Pre-eclampsia and Its Clinical Significance

Therapeutic effects of anticoagulant agents on preeclampsia in a murine model induced by phosphatidylserine/phosphatidylcholine microvesicles.

Chitosan‐Low molecular weight heparin sodium nanoparticles regulate Treg/Th17 immune balance and inflammation at the maternal‐fetal interface to ameliorate pre‐eclampsia by HB‐EGF

WNT pathways and upper limb anomalies

Analyzing clinical features and forecasting pregnancy outcomes of early-onset severe preeclampsia

Alternations of maternal and cord plasma hemostasis in preeclampsia before and after delivery.